Information  X 
Enter a valid email address

Ergomed plc (ERGO)

  Print   

Thursday 17 June, 2021

Ergomed plc

Board Change

RNS Number : 1702C
Ergomed plc
17 June 2021
 

 

 

PRESS RELEASE

 

 

Board Change

 

Guildford, UK - 17 June 2021: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a company focused on providing specialised services to the pharmaceutical industry, today announces that Rolf Soderstrom has informed the Board of his intention to  step down from the Board to focus on his other business activities, in particular his executive role as Chief Financial Officer of Syncona Investment Management Limited. Mr Soderstrom will remain on the Board until 30 September 2021 to provide a period of transition.

Dr Miroslav Reljanović, Executive Chairman of Ergomed, commented: "Rolf has brought tremendous value to the Ergomed Board since joining in 2019 and made a significant contribution to the growth and success we have shown during the recent period. On behalf of the Board, I would like to thank him for his considerable input and wish him well in all his future endeavours."

Rolf Soderstrom said: "It has been a pleasure to play a part in Ergomed's success since its strategic transition to a fully services-based business model. Its continued strong growth, track record of effective M&A and the quality of the management team and Board mean it is exceptionally well positioned to deliver on its vision of global leadership in specialised pharmaceutical services addressing unmet medical needs and patient safety."

ENDS

Enquiries:

 

Ergomed plc

 Tel: +44 (0) 1483 402 975

Miroslav Reljanović (Executive Chairman)


Richard Barfield (Chief Financial Officer)




Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Freddie Barnfield / Matthew O'Dowd (Nominated Adviser)


James Black (Broker)




Consilium Strategic Communications

Tel: +44 (0) 20 3709 5700

Chris Gardner / Matthew Neal

[email protected]

Angela Gray

 

 




About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand and a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO). For further information, visit: http://ergomedplc.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOASFMEEMEFSEEM

a d v e r t i s e m e n t